Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03347110 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
NCT03347110: Completed Phase 2 study, sponsored by UCB Biopharma SRL.
NCT03347110 is a Phase 2 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 184 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03347110, a Phase 2 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
Study Summary
This is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs were defined as events with onset date on
Interventions
- DRUG Bimekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2017-11-22 |
| Est. Completion | 2020-10-29 |
| Phase | Phase 2 |
What the finished NCT03347110 record still lists
NCT03347110 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% higher).
The record links to 0 conditions, and to 1 intervention - of which Bimekizumab is the first listed.
NCT03347110 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03347110 about?
NCT03347110 is a clinical study titled "A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis". This is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis
What is the current status of trial NCT03347110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2017-11-22. Estimated completion is 2020-10-29.
What interventions are being tested in trial NCT03347110?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT03347110?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03347110's enrollment target sits among peer trials
184 360th of 2000 higher than 1,638 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI